In conclusion, BCR-induced regulation of eIF4A may be a critical signal-dependent nexus for therapeutic attack in CLL and other B-cell malignancies, especially those dependent on MYC and/or MCL1. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.